Abbott Laboratories (NYSE:ABT) shares, rose in value, with the stock price down by -0.69% to the previous day’s close as strong demand from buyers drove the stock to $132.02.
Actively observing the price movement in the last trading, the stock closed the session at $132.94. The PE ratio was 17.13 over 12-month period. Referring to stock’s 52-week performance, its high was $141.23, and the low was $99.71. On the whole, ABT has fluctuated by 1.92% over the past month.
With the market capitalization of Abbott Laboratories currently standing at about $229.69 billion, investors are eagerly awaiting this quarter’s results, scheduled for in June. The company’s Forward Dividend Ratio is 2.28, with its dividend yield at 1.73%.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABT’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 1.66, with the price of ABT currently trading nearly -0.39% and 1.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.60, while the 7-day volatility ratio is showing 1.04% which for the 30-day chart, stands at 1.26%. Furthermore, Abbott Laboratories (ABT)’s beta value is 0.73, and its average true range (ATR) is 2.66.
A comparison of Abbott Laboratories (ABT) with its peers suggests the former has fared considerably weaker in the market. ABT showed an intraday change of -0.69% in last session, and over the past year, it grew by 26.66%%.
Data on historical trading for Abbott Laboratories (NYSE:ABT) indicates that the trading volumes over the past 3 months, they’ve averaged 7.35 million. According to company’s latest data on outstanding shares, there are 1.74 billion shares outstanding.
Nearly 0.67% of Abbott Laboratories’s shares belong to company insiders and institutional investors own 79.85% of the company’s shares. The stock has risen by 16.72% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABT stock heading into the next quarter.
